Anika Therapeutics(US:ANIK)2021-05-07 14:32Financial Performance - Total revenue decreased by 3% to $343 million due to COVID-19 dynamics[12] - Joint Preservation and Restoration revenue increased by 55% to $122 million, primarily due to acquisitions and hybrid sales channel momentum[12] - Joint Pain Management revenue decreased by 24% to $193 million, impacted by COVID-19 and related ordering patterns[12] - The company holds a solid cash position with approximately $946 million in cash and investments[4] - Net income was $2838 million, or $020 per share[12, 20] - Adjusted EBITDA was $4783 million[12, 26] Future Outlook and Strategy - The company expects a second-half 2021 market recovery as COVID-19 restrictions lift[4] - The company is well-positioned for high single-digit to low double-digit revenue growth in 2021[14] - The company aims to double revenue by 2024 compared to 2019 base year results and achieve double-digit adjusted EBITDA growth[6, 14] - The company plans to expand its market opportunity from $1 billion to over $8 billion[6]